ClinicalTrials.gg
RecruitingNCT06541691COATED-AIRUpdated Mar 19, 2025

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

An interventional study of Enteric-coated aspirin and Plain aspirin in Atherosclerotic Cardiovascular Disease, Coronary Artery Disease and Ischemic Heart Disease, sponsored by Rajaie Cardiovascular Medical and Research Center. Recruiting at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Primary conditionPeripheral Arterial DiseaseRegistry: AtherosclerosisReclassifiedWhy we changed it
Registry
Atherosclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Peripheral Arterial Disease
Why
  1. The study's listed conditions name Peripheral Arterial Disease, a narrower term within Atherosclerosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rajaie Cardiovascular Medical and Research Center · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Mar 2024, registered Aug 2024).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing aspirin in Peripheral Arterial Disease — 4 open to participants now, 5 under way, none of them phase 3. Aspirin · Peripheral Arterial Disease.

Planned enrollment
2nd of 13
3,000 · median 150
Started
2024
the only one that year
No phase
6 of 13
3 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Rajaie Cardiovascular Medical and Research Center

Among the 13 studies testing aspirin in Peripheral Arterial Disease, this one is the 2nd largest by planned enrollment, is the only one that started in 2024, is one of 6 with no phase, and was the 9th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

4 of the 13 studies testing aspirin in Peripheral Arterial Disease are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing aspirin in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days versus usual care. Both randomization are powered for clinical outcomes and the results will inform practice.

Read the detailed description
  • Background: Aspirin is a key treatment option of patients with atherosclerotic cardiovascular disease (ASCVD). The enteric coating has emerged as a potential solution to minimize the exposure of the gastric mucosa to the medication. However, change in the medication main site of absorption might negatively impact the pharmacokinetics/pharmacodynamics of aspirin and alter its antithrombotic properties, leading to diminished efficacy of the medication. A sufficiently large randomized controlled trial with a long-term follow-up to compare the effectiveness of enteric-coated versus plain aspirin in reducing adverse cardiovascular events and mitigating the adverse effects of the medication in patients with ASCVD is lacking.

Ambient air pollution is a prominent cause of mortality, being associated with 6.7 million deaths worldwide every year, half of which are attributable to cardiovascular causes. Near the half of these deaths is attributable to cardiovascular causes. Several patient-level interventions have been proposed to counteract with the adverse effects of the air pollution, including alerting patients via text message, staying at home, using face masks, or consuming citrus fruits (as a source of vitamin C) during the days with air pollution. However, the effect of implementing these strategies, individually and especially as a group, in mitigating the adverse effects of the air pollution has not yet been studied in a randomized controlled trial powered for clinical outcomes.

The purpose of the current randomized clinical trial is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion, and an open-label comparison of a multifaceted intervention including a one-page informational flashcard, cell phone message alerting on days with poor air quality to encourage patients not to spend time outdoors or to wear KN-95 facemasks outdoors in those days, and encouraging patients to consume citrus fruits on highly polluted days (hereafter referred to as hybrid strategy), versus usual care, in a multicenter randomized controlled trial (RCT) with a 2x2 factorial design.

  • Design and Randomization method: Multicenter randomized controlled trial with a 2x2 full factorial design with double-blind randomization with a 1:1 allocation ratio to low-dose enteric-coated vs plain aspirin, and open-label randomization with 1:1 allocation ratio to hybrid strategy to reduce the cardiovascular effects of air pollution vs usual care. Permuted block randomization with block sizes of 8, 12 and 16 chosen randomly via an electronic web-based system will be used for the study. The allocation sequence will be concealed. All outcomes will be adjudicated by a Clinical Events Committee blinded to the assigned treatments.
  • Setting: Teaching hospitals in Tehran province, Iran will be involved.
  • Statistical consideration and sample size calculation: An event-driven approach was considered for the calculation of sample size. Considering a relative hazard reduction of 23% in the first (aspirin formulation) randomization and 25% in the second (air pollution mitigation strategy) randomization, to provide a two-sided alpha of 0.05 and a statistical power of 80%, a total number of 460 primary efficacy outcomes for the first randomization and 380 primary efficacy outcomes for the second randomization would be needed. An event-rate of 18.5% for the incidence of primary efficacy outcome in the control arm of the first randomization, and 19.2% for the incidence of primary efficacy outcome in the control arm of the second randomization was assumed per a median follow-up of 2-year. Ultimately, Considering 4% dropout rate per each randomization, a total number of 2920 and 2732 patients would be needed for the first and second randomizations, respectively.
03

Conditions studied

  • Atherosclerotic Cardiovascular Disease
  • Coronary Artery Disease
  • Ischemic Heart Disease
  • Ischemic Stroke
  • Peripheral Arterial Disease
  • Carotid Artery Stenosis
  • Carotid Atherosclerosis

Keywords

  • atherosclerosis
  • atherosclerotic cardiovascular disease
  • atherosclerotic arterial disease
  • atherosclerotic plaque
  • coronay artery disease
  • ischemic heart disease
  • atherosclerotic disease
  • ischemic stroke
  • peripheral arterial disease
  • carotid artery stenosis
  • carotid atherosclerosis
  • myocardial infarction
  • acute limb ischemia
  • bleeding
  • major bleeding
  • gastrointestinal bleeding
  • gastrointestinal ulcer
  • peptic ulcer disease
  • gastric ulcer
  • duodenal ulcer
  • dyspepsia
  • intracerebral hemorrhage
  • aspirin
  • acetylsalicylic acid
  • antithrombotic therapy
  • antithrombotic agents
  • antiplatelet agents
  • air pollution
  • cerebral hemorrhage
  • hemorrhage
04

In context

Peripheral Arterial Disease Reclassified

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Rajaie Cardiovascular Medical and Research Center is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Compared within Peripheral Arterial Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Atherosclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years) with documented ASCVD defined as at least one of the following:

    • Coronary artery disease (CAD):

      1. Previous or recent documented type I myocardial infarction *(if not specified, will be assumed as type I)
      2. History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
      3. History of obstructive CAD (>50% stenosis) documented by coronary computed tomography (CT) or conventional angiography
    • Peripheral arterial disease (PAD):

      1. Previous or recent acute ischemic limb event (>7 days prior)
      2. History of previous endovascular/surgical lower or upper extremities revascularization for an atherosclerotic cause
      3. History of ulcer or lower extremities amputation due to ASCVD.
    • Carotid arterial diseases:

      1. History of previous endovascular/surgical carotid artery revascularization for atherosclerotic causes
      2. History of > 50% carotid artery stenosis based on documented imaging tests (Duplex US, CT angiography, magnetic resonance angiography, or conventional angiography)
    • Ischemic stroke:

      1. History of recent or previous documented ischemic stroke not due to atrial fibrillation, endocarditis, or systemic hypoperfusion/hypotension, being treated with low-dose aspirin
  • Inhabitant of Tehran province
  • Willing to participate and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Being within 72 days of acute/unstable atherosclerotic cardiovascular events (acute myocardial infarction, acute limb event, and acute ischemic stroke), or within 72 hours of revascularization.
  • Patients receiving triple antithrombotic therapy
  • History of upper gastrointestinal bleeding within the past 30 days
  • History of intracranial hemorrhage within the past 30 days
  • End-stage kidney disease with estimated \< 15 mL/min, or undergoing hemodialysis or peritoneal dialysis
  • Known comorbidities associated with poor prognosis (e.g., cancer) in conjunction with an estimated of less than one year according to the treating clinician
  • Any other conditions that make the participants unsuitable for recruitment or follow-up (e.g., illiteracy)
  • Not having aspirin as part of the planned durable treatment regimen
  • Inability to receive/read text messages/phone calls by personal mobile phone (or that of a caregiver who lives with the patient and is willing to relay messages)

    • The full list of exclusion criteria is provided in the study protocol
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    Enteric-coated aspirin (+/- hybrid strategy)

    81 mg enteric-coated aspirin (+/- a hybrid strategy to mitigate the cardiovascular adverse effects of the air pollution)

    Drug: Enteric-coated aspirin

  • Active comparator
    Plain aspirin (+/- hybrid strategy)

    81 mg plain aspirin (+/- a hybrid strategy to mitigate the cardiovascular adverse effects of the air pollution)

    Drug: Plain aspirin

  • Experimental
    Hybrid strategy (with enteric-coated or plain aspirin)

    A hybrid strategy to mitigate the cardiovascular adverse effects the air pollution, composed of one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days.

    Other: Hybrid strategy

  • No intervention
    Usual care (with enteric-coated or plain aspirin)

    No active strategy (usual care) without any clear recommendations related to air pollution; only a control card will be shared with the patients randomized to the usual care

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enteric-coated aspirin tablet 81 mg, once daily

    Also known as: Low dose of enteric-coated aspirin

  • DrugPlain aspirin

    Plain aspirin tablet 81 mg, once daily

    Also known as: Low dose of plain aspirin

  • OtherHybrid strategy

    A hybrid strategy composed from: * A one-page educational flashcard * Alerting patients on highly polluted days via text message * Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days * Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days * Encouraging patients to consume citrus fruits during highly polluted days

    Also known as: The hybrid strategy to mitigated the cardiovascular adverse effects of the air pollution

07

What researchers measure

Primary outcomes

  1. Composite of fatal or nonfatal ischemic stroke (not deemed to be related to systemic hypotension), type I myocardial infarction, and acute limb events

    Time to the first occurrence of an outcome composed of any endpoint that fulfills the definite criteria for diagnosis of at least one of the ischemic stroke, type I myocardial infarction, or acute limb event (whether leading to the patient's death or not) as defined in the description of the related secondary outcomes This outcome is assigned as the primary efficacy outcome for the first randomization.

    Time frame: within maximum of 30-month follow-up

  2. Composite of non-fatal ischemic stroke (not deemed to be related to systolic hypotension), type I myocardial infarction, acute limb events, or cardiovascular death

    Time to the first occurrence of an outcome composed of any endpoint that fulfills the definite criteria for diagnosis of at least one of the ischemic stroke, type I myocardial infarction, or acute limb event, and don not result in patient death as defined in the description of the related secondary outcomes This outcome is assigned as the primary outcome for the second randomization.

    Time frame: within maximum of 30-month follow-up

Secondary outcomes

  1. Type I myocardial infarction

    Time to the first occurrence of type I myocardial infarction. Type I myocardial infarction is defined as spontaneous clinical syndrome related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection, with resulting intraluminal thrombus and leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. This classification requires the detection of a rise and/or fall of cardiac biomarker values (preferably cTn) with at least 1 value \>99th percentile of the URL and at least 1 of the following: 1- Symptoms of myocardial ischemia 2- New or presumed new significant ST-segment T wave changes or new left bundle branch block on the ECG 3- Development of pathological Q waves on the ECG 4- Imaging evidence of new loss of myocardium or new regional wall motion abnormality 5- Identification of an intracoronary thrombus by angiography or autopsy

    Time frame: within maximum of 30-month follow-up

  2. Ischemic stroke (not deemed to be related to systemic hypotension)

    Time to the first occurrence of ischemic stroke. Ischemic stroke is defined as an episode of acute neurological dysfunction caused by focal cerebral, spinal, or retinal infarction as a result of arterial thrombosis and/or thromboembolism (not deemed to be related to systemic hypotension/hypoperfusion), and lasting ≥ 24 hours or to time of death with residual neurological sequelae

    Time frame: within maximum of 30-month follow-up

  3. Acute limb event

    A limb-threatening ischemia that is confirmed by limb hemodynamics or imaging and leads to an acute vascular intervention (i.e., pharmacologic \[heparin, thrombolysis\], peripheral arterial surgery/reconstruction, peripheral angioplasty/stenting, and/or limb amputation) within 30 days of onset of symptoms. In case of lack of confirmation by limb hemodynamics or imaging, the absence of pedal pulses is acceptable as the hemodynamic criterion for acute limb ischemia

    Time frame: within maximum of 30-month follow-up

  4. All-cause death

    Death due to any causes (cardiovascular, non-cardiovascular, or undetermined) within the follow-up period

    Time frame: within maximum of 30-month follow-up

  5. Cardiovascular death

    Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected: 1- Death caused by acute MI 2- Death caused by sudden cardiac, including unwitnessed, death 3- Death resulting from heart failure 4- Death caused by stroke 5- Death resulting from cerebrovascular hemorrhage 6- Death resulting from other cardiovascular causes such as PE, acute aortic syndromes, arrhythmia, and others

    Time frame: within maximum of 30-month follow-up

  6. Unplanned vascular hospitalization

    Inpatient admission to a hospital specifically due to acute events involving the vascular system. This encompasses conditions such as acute myocardial infarction, ischemic or hemorrhagic stroke, acute limb ischemia, and other vascular emergencies necessitating urgent medical care and hospitalization

    Time frame: within maximum of 30-month follow-up

  7. Composite of International Society on Thrombosis and Haemostasis (ISTH) major or clinically-relevant non-major gastrointestinal (GI) bleeding that bleeding and new symptomatic diagnosed gastroduodenal ulcer

    Time to the first occurrence of an outcome composed of any GI bleeding that fulfills the ISTH criteria for major or clinically-relevant non-major bleeding (defined in the description of the related secondary outcomes), and/or any newly diagnosed symptomatic gastroduodenal ulcer that meets the definition described in the description of the related secondary outcomes. This outcome is considered as the primary safety outcome for the first randomization.

    Time frame: within maximum of 30-month follow-up

  8. Upper GI bleeding

    Bleeding originating from sites in the esophagus, stomach, or duodenum with manifestations including hematemesis (vomiting of red blood or coffee-grounds material), melena (black, tarry stool), or hematochezia (passage of red or maroon material per rectum). Major and clinically relevant non-major UGIB will also be discriminated.

    Time frame: within maximum of 30-month follow-up

  9. Clinically relevant non-major GI bleeding

    Bleeding from the upper or lower gastrointestinal tract that meets the criteria for the ISTH definition for clinically-relevant non-major bleeding (Please see below for these two definitions).

    Time frame: within maximum of 30-month follow-up

  10. Any Major bleeding

    Any bleeding event fulfills the ISTH major bleeding criteria in non-surgical patients defined as having a symptomatic presentation and: 1- Fatal bleeding and/or 2- Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or 3- Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

    Time frame: within maximum of 30-month follow-up

  11. Intracranial hemorrhage

    The abnormal bleeding within the confines of the skull, involving either the brain tissue (intracerebral hemorrhage) or the spaces between the layers that cover the brain (subarachnoid or subdural hemorrhage).

    Time frame: within maximum of 30-month follow-up

  12. Any clinically relevant non-major bleeding

    Any sign or symptom of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 1- Requiring medical intervention by a healthcare professional 2- Leading to hospitalization or increased level of care 3- Prompting a face-to-face (i.e., not just a telephone or electronic communication) evaluation.

    Time frame: within maximum of 30-month follow-up

  13. New symptomatic diagnosed gastroduodenal ulcer

    Gastroduodenal ulcer manifested by gastrointestinal symptoms that persist for \> 3 days, with confirmation of ulcer by endoscopy. An ulcer is defined as any mucosal break at least 3 mm in greatest diameter

    Time frame: within maximum of 30-month follow-up

08

Study locations

1 of 1 sites recruiting
  • Rajaie Cardiovascular Medical and Research Center
    Tehran, 1995614331, Iran, Islamic Republic of
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 7, 2024
StartActual
Mar 6, 2024
Primary completionEst.
Mar 30, 2026
CompletionEst.
Mar 30, 2027
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06541691
Lead sponsor
Rajaie Cardiovascular Medical and Research Center
Responsible party
Parham Sadeghipour (Dr., Rajaie Cardiovascular Medical and Research Center) — Principal investigator
First posted
Aug 7, 2024
Start date
Mar 6, 2024
Primary completion
Mar 30, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Mar 19, 2025

Study contacts

Parham Sadeghipour, MD
Contact
psadeghipour@hotmail.com
+982123921 ext. 2092
Parham Sadeghipour, M.D
principal investigator · Rajaie Cardiovascular Medical and Research Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion